DDInter1938 DDInter1658
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vincristine {u} (Compound) resembles {v} (Compound) Voacamine
Vincristine {u} (Compound) treats {v} (Disease) muscle cancer
Vincristine {u} (Compound) binds {v} (Gene) TUBB
Vincristine {u} (Compound) upregulates {v} (Gene) TICAM1
Vincristine {u} (Compound) is included by {v} (Pharmacologic Class) Vinca Alkaloids
Vincristine {u} (Compound) downregulates {v} (Gene) BRCA1
Vincristine {u} (Compound) causes {v} (Side Effect) Respiratory distress
Vincristine {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) TUBB2A
Vincristine (Compound) resembles Vinorelbine (Compound)
Vincristine (Compound) resembles Voacamine (Compound)
Vincristine (Compound) treats muscle cancer (Disease)
Vincristine (Compound) binds TUBB (Gene)
Vincristine (Compound) upregulates TICAM1 (Gene)
Vincristine (Compound) is included by Vinca Alkaloids (Pharmacologic Class)
Vincristine (Compound) downregulates BRCA1 (Gene)
Vincristine (Compound) causes Respiratory distress (Side Effect)
Vincristine (Compound) binds TUBB2A (Gene) and Vincristine (Compound) upregulates TUBB2A (Gene)